Sign inCreate account

Report workspace tools

NCT04535505WITHDRAWNanonymous

Establishment a Nucleic Acid Rapid Detection Technology Platform for Detecting Pathogenic Bordetella and Its Drug Resistance Genes

Sponsor

Source record

Children's Hospital of Fudan University

Phase

Source record

Withdrawn

Modality

AI-normalized

small molecule

Target

AI-normalized

Pathogenic Bordetella species and their drug resistance genes, specifically targeting Bordetella pertussis and its erythromycin resistance mechanisms.

Indication / condition

AI-normalized

Pertussis

Intervention

Source record

Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology

Source & freshness

Source record

NCT ID

NCT04535505

Original source

ClinicalTrials.gov

Source last updated

Sep 14, 2022

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04535505

Title

Establishment a Nucleic Acid Rapid Detection Technology Platform for Detecting Pathogenic Bordetella and Its Drug Resistance Genes

Sponsor

Children's Hospital of Fudan University

Status

WITHDRAWN

Phase

Withdrawn

Condition raw

Pertussis

Condition normalized

Pertussis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Pathogenic Bordetella species and their drug resistance genes, specifically targeting Bordetella pertussis and its erythromycin resistance mechanisms.

Target normalized

Pathogenic Bordetella species and their drug resistance genes, specifically targeting Bordetella pertussis and its erythromycin resistance mechanisms.

Interventions

Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology

Public preview

Source record

The proposed CPA platform utilizing CRISPR technology aims to provide a rapid and accurate diagnostic tool for detecting Bordetella species and their associated drug resistance genes. Given the ongoing global concerns regarding pertussis outbreaks, this technology could address a significant unmet need in infectious disease diagnostics. However, the trial has been withdrawn, indicating potential challenges in development or execution. The competitive landscape includes existing diagnostic methods such as culture and PCR, which may limit market entry unless the new platform demonstrates superior accuracy and speed. Diligence is required to assess the reasons for withdrawal and any implications for future development or partnerships.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Establishment a Nucleic Acid Rapid Detection Technology Platform for Detecting Pathogenic Bordetella and Its Drug Resistance Genes

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04535505

Status

WITHDRAWN

Phase

Withdrawn

Sponsor

Children's Hospital of Fudan University

Executive brief

Investment-Ready Snapshot

The proposed CPA platform utilizing CRISPR technology aims to provide a rapid and accurate diagnostic tool for detecting Bordetella species and their associated drug resistance genes. Given the ongoing global concerns regarding pertussis outbreaks, this technology could address a significant unmet need in infectious disease diagnostics. However, the trial has been withdrawn, indicating potential challenges in development or execution. The competitive landscape includes existing diagnostic methods such as culture and PCR, which may limit market entry unless the new platform demonstrates superior accuracy and speed. Diligence is required to assess the reasons for withdrawal and any implications for future development or partnerships.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 14, 2022
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04535505

Indication

Pertussis

Modality

small molecule

Target

Pathogenic Bordetella species and their drug resistance genes, specifically targeting Bordetella pertussis and its erythromycin resistance mechanisms.

Intervention

Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.